Abstracts Archive - Page 2316 of 2605 - ACR Meeting Abstracts

Abstract Number: 1740 • 2013 ACR/ARHP Annual Meeting
12-Month Outcomes Associated With Belimumab In Patients With Systemic Lupus Erythematosus In Clinical Practice Settings: The Observe Study
Christopher E. Collins¹, Maria Dall'era², Alan Oglesby³, Michael B. McGuire⁴, Ramesh Pappu³, Hong Kan³ and Charles T. Molta⁵, ¹Rheumatology, Washington Hospital Center, Washington, DC, ²Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ³GlaxoSmithKline, Research Triangle Park, NC, ⁴Medical Data Analytics, Parsippany, NJ, ⁵GlaxoSmithKline, King of Prussia, PA
Background/Purpose: Large-scale clinical trials have demonstrated the clinical efficacy of belimumab in patients with systemic lupus erythematosus (SLE). We examined clinical outcomes associated with 12…
Abstract Number: 1741 • 2013 ACR/ARHP Annual Meeting
Correlation Of The Interferon Gene Signature With Systemic Lupus Erythematosus Disease Activity Is Dependent On The Associated Level Of The BAFF Gene Transcript
Michelle Petri¹, Laurence S. Magder², Hong Fang¹, Julie Czerkowicz³, Andrea Dearth³, Jadwiga Bienkowska⁴, Norm Allaire⁵, Patrick Cullen³, Alice Thai³ and Ann Ranger³, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD, ³Biogen Idec Inc, Cambridge, MA, ⁴Translational Medicine, Biogen Idec Inc., Cambridge, MA, ⁵Biogen Idec Inc., Cambridge, MA
Background/Purpose: The interferon alpha (IFN) gene signature is frequent in SLE (~50% of patients) and important in pathogenesis. However, multiple studies have found that the…
Abstract Number: 1742 • 2013 ACR/ARHP Annual Meeting
Effects Of Blisibimod, An Inhibitor Of B Cell Activating Factor, On Serum Immunoglobulins and Infection Risk In Patients With Systemic Lupus Erythematosus: Observations From The Placebo-Controlled Pearl-SC and Open-Label Extension Studies
Richard A. Furie¹, Matthew Thomas², Alvina Chu³, Renee S. Martin³, Colin Hislop³ and Morton A. Scheinberg⁴, ¹The Feinstein Institute for Medical Research and North Shore-Long Island Jewish Health System, Lake Success, NY, ²Health and Research Centre, Trivandrum, Kerala, India, ³Anthera Pharmaceuticals Inc, Hayward, CA, ⁴Rheumatology Hospital Abreu Sodre Pesquisa Clínica, São Paulo, Brazil
Background/Purpose: To evaluate the effects of subcutaneously-administered blisibimod (A-623, AMG 623), an inhibitor of B-cell activating factor (BAFF), on IgG, IgM and infection risk in patients…
Abstract Number: 1743 • 2013 ACR/ARHP Annual Meeting
Administration Of AMG 557, a Human Anti-B7RP-1 (ICOSL) Antibody, Leads To The Selective Inhibition Of Anti-KLH IgG Responses In Subjects With SLE: Results Of a Phase 1 Randomized, Double-Blind, Placebo-Controlled, Sequential, Rising, Multiple-Dose Study
Barbara Sullivan¹, Wayne H. Tsuji², Vishala L. Chindalore³, Thomas D. Geppert⁴, Alla Rudinskaya⁵, Patricia Pardo⁶, Alan Kivitz⁷, C. Michael Neuwelt⁸, Meggan Mackay⁹, R. John Looney¹⁰, J. Carter Thorne¹¹, Marilee Andrew¹², Greg Arnold¹³, Michael Boedigheimer¹, Kit Chiu¹, Cherie Green¹, Arunan Kaliyaperumal¹, Christine Wang¹⁴, Andrew Welcher¹ and James Chung¹, ¹Amgen, Thousand Oaks, CA, ²Clinical Research/Inflammation, Amgen, Seattle, WA, ³Anniston Medical Clinic PC, Anniston, AL, ⁴Metroplex Clinical Research Center, LLC, Dallas, TX, ⁵Danbury Hospital, Danbury, CT, ⁶MRA Clinical Research, Miami, FL, ⁷Altoona Center for Clinical Research, Duncansville, PA, ⁸East Bay Rheumatology Research Institute, San Leandro, CA, ⁹Autoimmune & Musculoskeletal Disease, Feinstein Institute for Medical Research, Manhasset, NY, ¹⁰Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, ¹¹Southlake Regional Health Centre, Newmarket, ON, Canada, ¹²Amgen, Seattle, WA, ¹³Medical Sciences, Amgen, Thousand Oaks, CA, ¹⁴Biostatistics, Amgen, Thousand Oaks, CA
Background/Purpose: The interaction of inducible costimulator (ICOS) with its ligand, B7-related protein-1 (B7RP-1 or ICOSL), plays a role in T cell differentiation, cytokine production, and…
Abstract Number: 1744 • 2013 ACR/ARHP Annual Meeting
Identifying Trajectories of Lung Function Change Over Time in Scleroderma
Ada Man¹, Todd Davidyock², Laura Western³, Michael Ieong², Yuqing Zhang⁴ and Robert W. Simms¹, ¹Rheumatology, Boston University School of Medicine, Boston, MA, ²Boston University School of Medicine, Boston, MA, ³University of Maryland, Baltimore, MD, ⁴Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA
Background/Purpose: Interstitial lung disease (ILD) is a leading cause of scleroderma (SSc) mortality, yet little is known about how changes in lung function over time…
Abstract Number: 1745 • 2013 ACR/ARHP Annual Meeting
Prediction Of Pulmonary Complications In Systemic Sclerosis – Model Development and Validation
Svetlana I. Nihtyanova¹, Benjamin E. Schreiber², Voon H. Ong³, John G. Coghlan⁴, Athol U. Wells⁵ and Christopher P. Denton⁶, ¹Department of Rheumatology, Royal Free and University College Medical School, London, United Kingdom, ²Royal Free Hospital NHS Foundation Trust, National Pulmonary Hypertension Service, London, United Kingdom, ³Department of Rheumatology, The Royal Free and University College Medical School, London, United Kingdom, ⁴National Pulmonary Hypertension Service, The Royal Free Hospital NHS Foundation Trust, London, United Kingdom, ⁵Royal Brompton and Harefield NHS Foundation Trust, Department of Radiology, London, United Kingdom, ⁶Centre for Rheumatology, Royal Free and University College Medical School, London, United Kingdom
Background/Purpose: Pulmonary complications contribute substantially to systemic sclerosis (SSc) associated morbidity and are the most frequent disease-related cause of death. We explore predictors of clinically…
Abstract Number: 1746 • 2013 ACR/ARHP Annual Meeting
Pericardial Effusions Are Not a Poor Prognostic Factor In Systemic Sclerosis Patients With Pulmonary Hypertension
Elana J. Bernstein¹, Jessica K. Gordon², Wei-Ti Huang³ and Virginia D. Steen⁴, ¹Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, ²Rheumatology, Hospital for Special Surgery, New York, NY, ³Biostatistics, Hospital for Special Surgery, New York, NY, ⁴Department of Rheumatology, Georgetown University Medical Center, Washington, DC
Background/Purpose: Pulmonary hypertension (PH) (defined as a mean pulmonary arterial pressure ≥ 25 mmHg on right heart catheterization) is a leading cause of death in…
Abstract Number: 1747 • 2013 ACR/ARHP Annual Meeting
Plasma MCP-1 and IL-10 Levels Predict Long-Term Progression Of Interstitial Lung Disease In Patients With Early Systemic Sclerosis
Minghua Wu¹, Claudia Pedroza², Gloria Salazar¹, Xiaodong Zhou¹, John D. Reveille¹, Maureen D. Mayes¹ and Shervin Assassi¹, ¹Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, ²Internal Medicine, University of Texas Health Science Center at Houston, Houston, TX
Background/Purpose: The currently available clinical markers are not reliable predictors of long-term progression of systemic sclerosis (SSc) related interstitial lung disease (ILD). SSc patients have…
Abstract Number: 1714 • 2013 ACR/ARHP Annual Meeting
Grey-Scale and Power Doppler Findings Of Lower Extremity Entheses In Healthy Children
Clara Lin¹ and Diana Milojevic², ¹Pediatric Rheumatology, University of California-San Francisco, San Francisco, CA, ²Dept of Pediatric Rheumatology, University of California, San Francisco, San Francisco, CA
Background/Purpose: The aim of our study is to describe the grey-scale and Power Doppler findings in lower extremity entheses in healthy children ages 5-18 years.…
Abstract Number: 1723 • 2013 ACR/ARHP Annual Meeting
Lesinurad, An Inhibitor Of The Uric Acid Transporter URAT1 and a Potential Therapy For Gout, Requires URAT1 Phenylalanine 365 For High Affinity Inhibition
Philip K. Tan, David Hyndman and Jeffrey N. Miner, Ardea Biosciences, Inc., San Diego, CA
Background/Purpose: Gout is caused by a lack of efficient excretion of uric acid, resulting in hyperuricemia and the formation of crystal deposits of uric acid. …
Abstract Number: 1706 • 2013 ACR/ARHP Annual Meeting
Fine-Mapping Major Histocompatibility Complex Variation Associated With Ankylosing Spondylitis Susceptibility
Adrian Cortes¹, International Genetics of Ankylosing Spondylitis Consortium (IGAS)², Paul de Bakker³ and Matthew A. Brown⁴, ¹Human Genetics Group, The University of Queensland Diamantina Insititute, Brisbane, Australia, ²University of Queensland Diamantina Institute, brisbane, Australia, ³Medical Genetics, University Medical Center Utrecht, Utrecht, Netherlands, ⁴University of Queensland Diamantina Institute, Brisbane, Australia
Background/Purpose: Ankylosing spondylitis (AS) is a common, highly heritable, inflammatory arthritis. Thus far, 27 susceptibility loci have been identified in and outside the MHC in…
Abstract Number: 1707 • 2013 ACR/ARHP Annual Meeting
Biological Insights From Genetics Of Rheumatoid Arthritis Contribute To Drug Discovery
Yukinori Okada^1,2,3, Di Wu^2,4,5,6, Chikashi Terao^7,8, Katsunori Ikari⁹, Yuta Kochi¹⁰, Koichiro Ohmura¹¹, Akari Suzuki¹⁰, Hisashi Yamanaka⁹, Joshua C. Denny¹², Jeffrey D. Greenberg¹³, Robert R. Graham¹⁴, Matthew A. Brown¹⁵, Sang-Cheol Bae¹⁶, Jane Worthington¹⁷, Leonid Padyukov¹⁸, Lars Klareskog¹⁹, Peter K. Gregersen²⁰, Peter M. Visscher^21,22, Katherine A. Siminovitch^23,24 and Robert M. Plenge²⁵, ¹Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ²Division of Genetics, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ³Broad Institute, Cambridge, MA, ⁴Division of Rheumatology, Immunology, and Allergy, Brigham and Women’s Hospital, Boston, MA, ⁵Program in Medical and Population Genetics, Broad Institute, Cambridge, MA, ⁶Department of Statistics, Harvard University, Cambridge, MA, ⁷Center for Genomic Medicine, Kyoto University, Kyoto, Japan, ⁸Department of Rheumatology and Clinical immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ¹⁰Laboratory for Autoimmune Diseases, Center for Integrative Medical Sciences, RIKEN, Yokohama, Japan, ¹¹Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ¹²Department of Biomedical Informatics, Vanderbilt University School of Medicine, Nashville, TN, ¹³Rheumatology, NYU Hospital for Joint Diseases, New York, NY, ¹⁴ITGR Human Genetics, Genentech, Inc., South San Francisco, CA, ¹⁵Human Genetics Group, The University of Queensland Diamantina Insititute, Brisbane, Australia, ¹⁶Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ¹⁷Arthritis Research UK Epidemiology Unit, Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, ¹⁸Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden, ¹⁹Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ²⁰Genomics and Human Genetics, Feinstein Institute for Medical Research, Manhasset, NY, ²¹The University of Queensland Diamantina Institute, Princess Alexandra Hospital, University of Queensland, Brisbane, Australia, ²²Queensland Brain Institute, The University of Queensland, St Lucia, Brisbane, Australia, ²³Mount Sinai Hospital, Toronto, ON, Canada, ²⁴University of Toronto, Toronto, ON, Canada, ²⁵Division of Rheumatology, Immunology and Allergy and Division of Genetics, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
Background/Purpose: A major challenge in human genetics is to devise a systematic strategy to integrate disease-associated variants with diverse genomic and biological datasets to provide…
Abstract Number: 1708 • 2013 ACR/ARHP Annual Meeting
Can People With Rheumatoid Arthritis Self Monitor Their Disease Activity?
Noura AL Osaimi¹, Erin Carruthers², Charles H Goldsmith^3,4, Paul M Adam⁵ and Diane Lacaille^1,6, ¹Medicine, University of British Columbia, Vancouver, BC, Canada, ²Arthritis Research Centre of Canada, Richmond, BC, Canada, ³Biostatistics, Arthritis Research Centre of Canada, Richmond, BC, Canada, ⁴Health Sciences, Simon Fraser University, Burnaby, BC, Canada, ⁵Rheumatology Liaison, Mary Pack Arthritis Centre, Vancouver, BC, Canada, ⁶Rheumatology, Arthritis Research Centre of Canada, University of British Columbia, Richmond, BC, Canada
Background/Purpose: In rheumatoid arthritis (RA) the target for treatment is clinical remission or minimal disease activity. Active involvement of patients in monitoring their own disease…
Abstract Number: 1709 • 2013 ACR/ARHP Annual Meeting
Rheumatoid Arthritis Patient Cardiovascular Disease Prevention Experiences: Qualitative Analysis and Implications
Christie M. Bartels¹, Sarah Tweddell², Barbara Bowers³, Elizabeth Jacobs⁴ and Tonya Roberts³, ¹Rheumatology/Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, ²UW School of Medicine and Public Health, Madison, WI, ³UW School of Nursing, Madison, WI, ⁴Internal Medicine, UW School of Medicine and Public Health, Madison, WI
Background/Purpose: Although rheumatoid arthritis (RA) increases cardiovascular disease (CVD) risk, RA patients receive less CVD preventive care than peers. We previously showed gaps in lipid…
Abstract Number: 1711 • 2013 ACR/ARHP Annual Meeting
Folic Acid Prescription Among Older Adult Methotrexate Initiators Is Poor
Gabriela Schmajuk¹, Jinoos Yazdany², Yinghui Miao³, David I. Daikh⁴ and Michael Steinman³, ¹Rheumatology, UCSF / San Francisco VA Medical Center, San Francisco, CA, ²Medicine, University of California, San Francisco, San Francisco, CA, ³Division of Geriatrics, UCSF, San Francisco Veterans Affairs Medical Center, San Francisco, CA, ⁴Rheumatology, University of California, San Francisco, San Francisco, CA
Background/Purpose: Methotrexate (MTX) is the most commonly used disease modifying agent for rheumatoid arthritis (RA), although liver enzyme (LFT) elevations limit its use in some…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].